EP1139754A4 - 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy - Google Patents

3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Info

Publication number
EP1139754A4
EP1139754A4 EP99966725A EP99966725A EP1139754A4 EP 1139754 A4 EP1139754 A4 EP 1139754A4 EP 99966725 A EP99966725 A EP 99966725A EP 99966725 A EP99966725 A EP 99966725A EP 1139754 A4 EP1139754 A4 EP 1139754A4
Authority
EP
European Patent Office
Prior art keywords
heteroarylidenyl
protein kinase
kinase activity
cancer chemotherapy
modulating protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99966725A
Other languages
German (de)
French (fr)
Other versions
EP1139754A1 (en
Inventor
Peter J Langecker
Laura Kay Shawver
Peng Cho Tang
Li Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of EP1139754A1 publication Critical patent/EP1139754A1/en
Publication of EP1139754A4 publication Critical patent/EP1139754A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99966725A 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy Withdrawn EP1139754A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11431398P 1998-12-31 1998-12-31
US114313P 1998-12-31
PCT/US1999/031232 WO2000038519A1 (en) 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Publications (2)

Publication Number Publication Date
EP1139754A1 EP1139754A1 (en) 2001-10-10
EP1139754A4 true EP1139754A4 (en) 2002-12-18

Family

ID=22354480

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99966725A Withdrawn EP1139754A4 (en) 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Country Status (10)

Country Link
EP (1) EP1139754A4 (en)
JP (1) JP2002533360A (en)
KR (1) KR20010108063A (en)
CN (1) CN1356872A (en)
AU (1) AU760964B2 (en)
BR (1) BR9916735A (en)
CA (1) CA2357042A1 (en)
IL (1) IL143920A0 (en)
MX (1) MXPA01006742A (en)
WO (1) WO2000038519A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DK1233943T3 (en) * 1999-11-24 2011-08-15 Sugen Inc Ionizable indolinone derivatives and their use as PTK ligands
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
MXPA02008021A (en) * 2000-02-15 2004-04-05 Sugen Inc Pyrrole substituted 2 indolinone protein kinase inhibitors.
BR0108728A (en) * 2000-02-28 2003-12-30 Aventis Pharma Sa Pharmaceutical Combination Therapy, and, Method for Treating a Cancer.
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
JP2004529904A (en) 2001-03-14 2004-09-30 ブリストル−マイヤーズ　スクイブ　カンパニー Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AR038957A1 (en) * 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
WO2003035619A1 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003035616A2 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003035614A2 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002346457A1 (en) * 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Pharmaceutical formulations comprising indolinone derivatives
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
CA2489813A1 (en) 2002-06-25 2003-12-31 Wyeth Use of thio-oxindole derivatives in treatment of hormone-related conditions
RU2005101624A (en) 2002-06-25 2005-06-27 Уайт (Us) APPLICATION OF THIOXINDOL DERIVATIVES IN THERAPY OF SKIN DISORDERS
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US20050239852A1 (en) 2002-08-02 2005-10-27 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
CA2506085A1 (en) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
NZ546645A (en) 2003-10-23 2010-02-26 Ab Science 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
CN100432071C (en) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 Substituted 1H-indole-2-ketone compound and its preparation method and uses
CA2603826C (en) 2005-04-04 2013-03-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
US8246966B2 (en) 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
EP2088863A2 (en) 2006-11-22 2009-08-19 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
ES2671730T3 (en) * 2011-11-11 2018-06-08 Eli Lilly And Company Combination therapy for ovarian cancer
US11083755B2 (en) 2015-01-08 2021-08-10 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
LT3288940T (en) 2015-04-29 2021-05-10 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
CN105585558A (en) * 2015-12-15 2016-05-18 贵州大学 Double-alkoxy pyrimidine jointing 3-ethylenic-bond-oxoindole derivative and preparing method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Also Published As

Publication number Publication date
MXPA01006742A (en) 2004-04-21
CN1356872A (en) 2002-07-03
IL143920A0 (en) 2002-04-21
AU2221500A (en) 2000-07-31
JP2002533360A (en) 2002-10-08
EP1139754A1 (en) 2001-10-10
AU760964B2 (en) 2003-05-22
BR9916735A (en) 2001-09-25
CA2357042A1 (en) 2000-07-06
WO2000038519A1 (en) 2000-07-06
KR20010108063A (en) 2001-12-07

Similar Documents

Publication Publication Date Title
EP1139754A4 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
IL146094A0 (en) Diaminothiazoles and their use for inhibiting protein kinases
HUP0200403A2 (en) Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use
EP1066286A4 (en) Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
ZA989249B (en) Heteroaromatic compounds and their use in medicine.
HRP980010B1 (en) Quinoline and quinazoline compounds useful in therapy
GB2337200B (en) Smoking substance for use in therapy
IL114418A0 (en) Tumor necrosis factor receptor-II associated protein kinase and methods for its use
IL206604A0 (en) Transmembrane protein expressed in prostate cancer
EP1112354A4 (en) Novel protein kinase molecules and uses therefor
HUP0103079A3 (en) Modulating multiple lineage kinase proteins
GB9816761D0 (en) Herpesvirus preparations and their uses
ZA985999B (en) Protein kinases and uses thereof
AU4686299A (en) Nek-related and bub1-related protein kinases
AU2113899A (en) Human protein kinase molecules
AU1456899A (en) Human protein kinase and kinase inhibitors
IL147345A0 (en) Drosphila recombination- associated protein and methods for use
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
GB9703633D0 (en) Cancer therapy
GB9803399D0 (en) Protein kinase c
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
GB9613629D0 (en) Reg gene expression in cancer tissue
ZA987206B (en) Cycline-dependent protein kinase-activating kinase and its uses
IL136210A0 (en) Reagent for tumor therapy and/or imaging
EP1071696A4 (en) Programmed cell death and caspase-12

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010730

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SUN, LI

Inventor name: TANG, PENG, CHO

Inventor name: SHAWVER, LAURA, KAY

Inventor name: LANGECKER, PETER, J.

A4 Supplementary search report drawn up and despatched

Effective date: 20021107

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 43/38 A, 7A 61K 31/40 B, 7A 61K 31/505 B

17Q First examination report despatched

Effective date: 20030915

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040126